Ethoxycarbonyl Group

Ethoxycarbonyl Group

SCHEMBL27713752

CCOC=O.Clc1cnccn1

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 6/20 0.35
RAB9A P51151 5/20 0.35
NPC1 O15118 4/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 6/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CDC7 O00311 1/20 0.31
DBF4 Q9UBU7 1/20 0.31
TSHR P16473 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP19A1 P11511 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethoxycarbonyl Group SCHEMBL27621641 0.81 KMT2A (0.37) KMT2ASMN1; SMN2RAB9ANPC1TP53
Ethoxycarbonyl Group SCHEMBL28036672 0.79 HSP90AA1 (0.55) KMT2ASMN1; SMN2RAB9ANPC1TP53
Ethoxycarbonyl Group SCHEMBL27836255 0.79 CDC7 (0.37) KMT2ASMN1; SMN2RAB9ANPC1TP53
Ethoxycarbonyl Group SCHEMBL28310600 0.78 MAPT (0.43) KMT2ASMN1; SMN2RAB9ANPC1TP53
Pyrazine SCHEMBL27608305 0.77 KMT2A (0.31) KMT2ANPSR1
Formamide SCHEMBL28216085 0.75 HSP90AA1 (0.41) KMT2AKDM4ETSHRCYP19A1TDP1
Formic Acid SCHEMBL27909158 0.75 KDM4E (0.40) KMT2ARAB9ANPC1KDM4ENPSR1
Pyrazine SCHEMBL28076131 0.75
Pyrazine SCHEMBL27608298 0.75
SCHEMBL29460909 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101115717-A Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists AVENTIS PHARMA INC (US) 2008-01-30 CN disclosed